AU8647101A - Compounds having activity as inhibitors of cytochrome p450rai - Google Patents

Compounds having activity as inhibitors of cytochrome p450rai

Info

Publication number
AU8647101A
AU8647101A AU8647101A AU8647101A AU8647101A AU 8647101 A AU8647101 A AU 8647101A AU 8647101 A AU8647101 A AU 8647101A AU 8647101 A AU8647101 A AU 8647101A AU 8647101 A AU8647101 A AU 8647101A
Authority
AU
Australia
Prior art keywords
inhibitors
compounds
activity
cytochrome p450rai
p450rai
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU8647101A
Other languages
English (en)
Inventor
Jayasree Vasudevan
Alan T Johnson
Dehua Huang
Li-Ming Wang
Roshantha A Chandraratna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/651,004 external-priority patent/US6369261B1/en
Priority claimed from US09/651,001 external-priority patent/US6291677B1/en
Priority claimed from US09/651,564 external-priority patent/US6380256B1/en
Priority claimed from US09/651,235 external-priority patent/US6252090B1/en
Priority claimed from US09/651,234 external-priority patent/US6387951B1/en
Priority claimed from US09/651,566 external-priority patent/US6369225B1/en
Priority claimed from US09/651,003 external-priority patent/US6303785B1/en
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Publication of AU8647101A publication Critical patent/AU8647101A/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/28—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
AU8647101A 2000-08-29 2001-08-14 Compounds having activity as inhibitors of cytochrome p450rai Pending AU8647101A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US09/651,004 US6369261B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,001 US6291677B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,564 US6380256B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,235 US6252090B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,234 US6387951B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,566 US6369225B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,003 US6303785B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
PCT/US2001/025443 WO2002018361A2 (en) 2000-08-29 2001-08-14 Compounds having activity as inhibitors of cytochrome p450rai

Publications (1)

Publication Number Publication Date
AU8647101A true AU8647101A (en) 2002-03-13

Family

ID=27569871

Family Applications (2)

Application Number Title Priority Date Filing Date
AU8647101A Pending AU8647101A (en) 2000-08-29 2001-08-14 Compounds having activity as inhibitors of cytochrome p450rai
AU2001286471A Ceased AU2001286471B2 (en) 2000-08-29 2001-08-14 Compounds having activity as inhibitors of cytochrome P450RAI

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001286471A Ceased AU2001286471B2 (en) 2000-08-29 2001-08-14 Compounds having activity as inhibitors of cytochrome P450RAI

Country Status (8)

Country Link
EP (1) EP1366036B1 (enExample)
JP (1) JP2004507531A (enExample)
AT (1) ATE315558T1 (enExample)
AU (2) AU8647101A (enExample)
CA (1) CA2420869A1 (enExample)
DE (1) DE60116642T2 (enExample)
ES (1) ES2256288T3 (enExample)
WO (1) WO2002018361A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313107B1 (en) * 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
JP5082033B2 (ja) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒのモジュレーター
US6740676B2 (en) * 2002-03-19 2004-05-25 Allergan, Inc. 4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA05003456A (es) 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
BRPI0413923A (pt) 2003-08-29 2006-11-07 Ono Pharmaceutical Co composto capaz de ligar o receptor de s1p e uso farmacêutico do mesmo
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US7226951B2 (en) 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
PL1826197T3 (pl) 2004-12-13 2012-06-29 Ono Pharmaceutical Co Pochodna kwasu aminokarboksylowego i jej zastosowanie lecznicze
AU2005316739A1 (en) 2004-12-13 2006-06-22 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
CA2598133A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
CN103402986A (zh) 2010-11-24 2013-11-20 阿勒根公司 S1p受体的调节剂
CA2848540A1 (en) 2011-09-15 2013-03-21 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Therapeutic compounds
WO2015109318A2 (en) 2014-01-17 2015-07-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Therapeutic methods
PT3204357T (pt) * 2014-10-10 2022-03-31 High Force Res Limited Retinoides sintéticos fluorescentes
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3475305D1 (en) * 1983-07-05 1988-12-29 Pfizer Carboxylic acid derivatives useful for inhibiting the degradation of cartilage
ZA875052B (en) * 1986-07-11 1989-03-29 Du Pont Angiotensin ii receptor blocking imidazoles
US5089509A (en) * 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5015658A (en) * 1988-06-29 1991-05-14 Allergan, Inc. Thiochroman esters of phenols and terephthallates having retinoid-like activity
US5045551A (en) * 1989-09-19 1991-09-03 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5023341A (en) * 1989-09-19 1991-06-11 Allergan, Inc. Compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity
US5202471A (en) * 1990-02-06 1993-04-13 Allergan, Inc. Alkyl, alkoxy and thioalkoxy substituted diphenyl acetylenes having retinoid like activity
US5134159A (en) * 1991-03-26 1992-07-28 Allergan, Inc. 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity
EP0800517A1 (en) * 1994-12-29 1997-10-15 Allergan Acetylenes disubstituted with a 5 or 8 substituted tetrahydronaphthyl or dihydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5489584A (en) * 1994-12-29 1996-02-06 Allergan, Inc. Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity

Also Published As

Publication number Publication date
EP1366036A2 (en) 2003-12-03
DE60116642T2 (de) 2006-11-09
HK1059439A1 (en) 2004-07-02
ES2256288T3 (es) 2006-07-16
WO2002018361A3 (en) 2003-07-31
DE60116642D1 (de) 2006-04-06
WO2002018361A2 (en) 2002-03-07
JP2004507531A (ja) 2004-03-11
ATE315558T1 (de) 2006-02-15
CA2420869A1 (en) 2002-03-07
AU2001286471B2 (en) 2006-09-07
EP1366036B1 (en) 2006-01-11

Similar Documents

Publication Publication Date Title
WO2002026727A3 (en) Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai
AU8647101A (en) Compounds having activity as inhibitors of cytochrome p450rai
DE50014190D1 (de) Verwendung von phthalazin-derivaten zur behandlung neurodegenerativer krankheiten
DE69927507D1 (de) Zusammensetzungen und verfahren zur behandlung von abnormaler zellvermehrung
NZ335981A (en) Ketobenzamides as calpain inhibitors
ATE411399T1 (de) Behandlung der huntington's krankheit mit epa
ATE354565T1 (de) Hydroxyethylamin-derivate für die behandlung von alzheimer
EP1549767A4 (en) MODULATION OF EXPRESSION OF FORKHEAD BOX O1A
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
BR0108452A (pt) Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
ATE395052T1 (de) Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
AU1373499A (en) Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease
BG101130A (bg) Инхибитори на интерлевкин 1 бета-конвертиращ ензим
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
WO2003024386A3 (en) Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
IL135921A0 (en) Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
WO2003002107A3 (en) Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
WO2003004006A8 (en) Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
DE60027127D1 (de) Verwendung von Polyaminosäurederivaten zur Behandlung von Seborrhoe und verwandten Hautstörungen
MXPA04004743A (es) Derivados de 2,3-diaril-pirazolidina activos hacia neurotensina.
DK1368023T3 (da) Anvendelse af buprenoprphin til behandling af urininkontinens
DE69905489D1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
WO2000073274A3 (de) Substituierte phenylcyclohexancarbonsäureamide und ihre verwendung als adenosinaufnahme-inhibitoren
WO2004001061A3 (en) Antisense modulation of heme oxygenase 1 expression
AU2422199A (en) Ustilipides, method for the production and the use thereof